Palvella Therapeutics (PVLA)Orbimed Advisors LLC opened a new position $16.8M

135K

Shares reported

0.34%

Disclosed portfolio weight

$16.8M

Reported value

Holdings as of

Mar 31, 2026

Filed

May 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 31, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
2. Apr 13, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 13, 2026 (the “ Appointment Date ”), the Board of Directors (the “ Board ”) of Palvella Therapeutics, Inc. (the “ Company ”) increased the size of the Board from six to seven members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed John Doux, M.D., to serve as a Class III director, with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders.”
3. May 7, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

What came next

1. Jun 10, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 10, 2026, at the 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”) of Palvella Therapeutics, Inc. (the “ Company ”), the Company’s stockholders approved the amendment (the “ Plan Amendment ”) to the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan to increase the authorized shares issuable thereunder by 750,000 shares.”
2. Jun 29, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 29, 2026 (the “Appointment Date”), the Board of Directors (the “Board”) of Palvella Therapeutics, Inc. (the “Company”) increased the size of the Board from seven to eight members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Matthew Pauls, to serve as a Class I director, with an initial term expiring at the Company’s 2027 Annual Meeting of Stockholders.”
3. Aug 4, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Palvella Therapeutics

For Palvella Therapeutics, OQRO holds 4 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PVLA page.

How this filing works

• SEC Form 13F

Other disclosures at Palvella Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 29, 2026
• SEC Form 13F-HRMay 15, 2026

Everything OQRO holds on this company is on its PVLA page.